Craig Denny, MD
Psychiatry · Idaho Falls, IDNPI 1720071319
Payments from drug & device makers
Across 621 payments — averaging $16.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$695
- Sunovion Pharmaceuticals Inc.$640
- Supernus Pharmaceuticals, Inc.$558
- plus $3K from 20 others
What the payments were for
- Food & beverage$9,99498%
- Education$2372%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 151 | $2,210 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 105 | $1,936 |
| Otsuka America Pharmaceutical, Inc. | 82 | $1,272 |
| Teva Pharmaceuticals USA, Inc. | 36 | $695 |
| Sunovion Pharmaceuticals Inc. | 42 | $640 |
| Supernus Pharmaceuticals, Inc. | 33 | $558 |
| Axsome Therapeutics, Inc. | 28 | $526 |
| Alkermes, Inc. | 28 | $411 |
| Lundbeck LLC | 24 | $395 |
| Vanda Pharmaceuticals Inc. | 14 | $323 |
| Ironshore Pharmaceuticals Inc. | 16 | $284 |
| Johnson & Johnson | 16 | $239 |
| Neurocrine Biosciences, Inc. | 8 | $141 |
| Merck | 8 | $138 |
| E.r. Squibb & Sons, L.L.C. | 4 | $67 |
| Eisai Inc. | 5 | $66 |
| Corium, LLC | 4 | $55 |
| Collegium Pharmaceutical, Inc. | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Shire North American Group Inc | 3 | $41 |
| Indivior Inc. | 2 | $35 |
| Arbor Pharmaceuticals, Inc. | 2 | $29 |
| Janssen Scientific Affairs, LLC | 1 | $27 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Tris Pharma Inc | 1 | $14 |
| Almatica Pharma LLC | 1 | $13 |
How this compares
$10,231 in reported general payments places this provider in the 95th percentile of 98 psychiatry providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 149 | $208,823 |
| Abilify MaintenaAripiprazole | 19 | $49,559 |
| AuvelityDextromethorphan Hbr/Bupropion | 37 | $38,463 |
| LybalviOlanzapine/Samidorphan Malate | 22 | $33,484 |
| Invega SustennaPaliperidone Palmitate | 12 | $29,348 |
| CaplytaLumateperone Tosylate | 15 | $25,491 |
| RexultiBrexpiprazole | 17 | $23,818 |
| BelsomraSuvorexant | 54 | $23,027 |
| NuedextaDextromethorphan Hbr/Quinidine | 18 | $19,739 |
| DayvigoLemborexant | 48 | $15,242 |
| FetzimaLevomilnacipran Hcl | 24 | $13,727 |
| TrintellixVortioxetine Hydrobromide | 18 | $11,518 |
| Aripiprazole | 59 | $10,477 |
| Vilazodone Hcl | 119 | $8,443 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 171 | $8,198 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Fetzima | $2,210 | $222,550173 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,272 | $73,37736 claims |
| Axsome Therapeutics, Inc.Auvelity | $526 | $38,46337 claims |
| Alkermes, Inc.Lybalvi | $411 | $33,48422 claims |
| Johnson & JohnsonInvega Sustenna | $239 | $29,34812 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,936 | $25,49115 claims |
| MerckBelsomra | $138 | $23,02754 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $46 | $16,06932 claims |
| Eisai Inc.Dayvigo | $66 | $15,24248 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 98 psychiatry providers in Idaho.
Other psychiatry in Idaho Falls
- Cristina Sanchez JaquezAmmon$28K
- Linda CarterPocatello$9K
- Janet GilbreathNampa$9K
- Olurotimi AshayeMeridian$8K
- Thomas HolmesLewiston$8K
- Albert CrookCoeur D'alene$5K
- Richard PinesBoise$4K
- Lawrence BantaCaldwell$3K
- Zachary MorairtyTwin Falls$2K
- David ThompsonBoise$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.